Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, executed multiple sales of common stock between May 14 and May 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E. Lowenthal, the President and CEO of ARS Pharmaceuticals, Inc. (SPRY), sold shares of common stock between May 14 and May 16, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• On May 14, 2024, Lowenthal sold 2,873 shares at a weighted average price of $9.0084 and 2,884 shares at a weighted average price of $9.0058.
• On May 15, 2024, he sold 2,381 shares at a weighted average price of $9.0547 and 2,766 shares at a weighted average price of $9.0403.
• On May 16, 2024, Lowenthal sold 44,746 shares at a weighted average price of $9.0581 and 44,350 shares at a weighted average price of $9.0577.
• The sales were conducted at prices ranging from $9.00 to $9.16 per share.
• Following these transactions, Lowenthal directly owns 4,315,313 shares of common stock.
• He also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Richard E. Lowenthal Charitable Remainder UniTrust, as well as shares held by his spouse.
• Kathleen Scott, Attorney-in-Fact, signed the report on May 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports stock sales under a pre-arranged trading plan, which doesn't inherently indicate positive or negative sentiment.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially leading to short-term price fluctuations.
• The market may interpret the sales as a lack of confidence in the company's future prospects, although the sales were conducted under a pre-arranged trading plan.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often conducted under pre-arranged trading plans to avoid accusations of insider trading. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among corporate executives to diversify their holdings and manage personal finances while avoiding insider trading concerns.
• The volume and frequency of these sales are within typical ranges observed for executives at similarly sized pharmaceutical companies.

Stakeholder Impact

• Shareholders may react to the news of executive stock sales, potentially influencing the stock price in the short term.
• Employees may be indirectly affected by any resulting stock price volatility.

Key Dates